198 related articles for article (PubMed ID: 32200202)
1. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.
Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Han Y; Xiao W; Wang Z; Shi W; Mao Y; Yu J; Xia G; Liu Y
Eur J Med Chem; 2019 Sep; 178():352-364. PubMed ID: 31200237
[TBL] [Abstract][Full Text] [Related]
3. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S
Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675
[TBL] [Abstract][Full Text] [Related]
4. Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.
Elzahabi HSA; Nossier ES; Khalifa NM; Alasfoury RA; El-Manawaty MA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):546-557. PubMed ID: 29482389
[TBL] [Abstract][Full Text] [Related]
5. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.
Huang Z; Zhao B; Qin Z; Li Y; Wang T; Zhou W; Zheng J; Yang S; Shi Y; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111541. PubMed ID: 31382120
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.
Zhao H; Hu X; Cao K; Zhang Y; Zhao K; Tang C; Feng B
Eur J Med Chem; 2018 Sep; 157():935-945. PubMed ID: 30165341
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and identification of a novel skeleton of N-(pyridin-3-yl) proline as a selective CDK4/6 inhibitor with anti-breast cancer activities.
Liang JW; Li WQ; Nian QY; Xie SH; Yang L; Meng FH
Bioorg Chem; 2022 Feb; 119():105547. PubMed ID: 34906858
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma.
Yuan K; Kuang W; Chen W; Ji M; Min W; Zhu Y; Hou Y; Wang X; Li J; Wang L; Yang P
Eur J Med Chem; 2022 Jan; 228():114024. PubMed ID: 34875521
[TBL] [Abstract][Full Text] [Related]
9. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening.
Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P
Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188
[No Abstract] [Full Text] [Related]
11. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.
Horiuchi T; Chiba J; Uoto K; Soga T
Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a PROTAC targeting ALK with in vivo activity.
Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
[TBL] [Abstract][Full Text] [Related]
14. Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.
Freeman-Cook KD; Hoffman RL; Behenna DC; Boras B; Carelli J; Diehl W; Ferre RA; He YA; Hui A; Huang B; Huser N; Jones R; Kephart SE; Lapek J; McTigue M; Miller N; Murray BW; Nagata A; Nguyen L; Niessen S; Ninkovic S; O'Doherty I; Ornelas MA; Solowiej J; Sutton SC; Tran K; Tseng E; Visswanathan R; Xu M; Zehnder L; Zhang Q; Zhang C; Dann S
J Med Chem; 2021 Jul; 64(13):9056-9077. PubMed ID: 34110834
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.
Fu Y; Tang S; Su Y; Lan X; Ye Y; Zha C; Li L; Cao J; Chen Y; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
Bioorg Med Chem Lett; 2017 Dec; 27(23):5332-5336. PubMed ID: 29074254
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 (cdk4/6) inhibitors: perspectives in cancer therapy and imaging.
Graf F; Mosch B; Koehler L; Bergmann R; Wuest F; Pietzsch J
Mini Rev Med Chem; 2010 Jun; 10(6):527-39. PubMed ID: 20370706
[TBL] [Abstract][Full Text] [Related]
17. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
[TBL] [Abstract][Full Text] [Related]
18. Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
Xu Z; Liu Y; Song B; Ren B; Xu X; Lin R; Zhu X; Chen C; Yang S; Zhu Y; Jiang W; Li W; Xia Y; Hu L; Chen S; Chan CC; Li J; Zhang X; Yang L; Tian X; Ding CZ
Bioorg Med Chem Lett; 2024 Jul; 107():129769. PubMed ID: 38670537
[TBL] [Abstract][Full Text] [Related]
19. Development of pteridin-7(8H)-one analogues as highly potent cyclin-dependent kinase 4/6 inhibitors: Synthesis, structure-activity relationship, and biological activity.
Li Q; Chen L; Ma YF; Jian XE; Ji JH; You WW; Zhao PL
Bioorg Chem; 2021 Nov; 116():105324. PubMed ID: 34509794
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Optimization of a Novel 2
Wei Y; Tang Y; Zhou Y; Yang Y; Cui Y; Wang X; Wang Y; Liu Y; Liu N; Wang Q; Li C; Ruan H; Zhou H; Wei M; Yang G; Yang C
J Med Chem; 2021 Jul; 64(13):9078-9099. PubMed ID: 34129329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]